Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen and Array BioPharma, Inc.

Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of Care

Release Date: March 26, 2019
Expiration Date: March 26, 2020
Media: Internet - based

Activity Overview

This Medical Crossfire® activity describes the latest advances in the treatment of metastatic colorectal cancer (mCRC). Panelists discuss all relevant aspects of diagnosis, treatment, molecular testing, clinical trial data, and appropriate methods for adverse event management. This activity also examines the place of targeted and immunotherapeutic treatments in current clinical use, as well as treatments in clinical development.

Benefits of Participation

  • Develop an appreciation of the targeted treatment options available in the management of mCRC
  • Recognize targetable mutations in mCRC and considerations in molecular testing
  • Contextualize clinical trial data in specific patient scenarios, including in patients with specific phenotypic and molecular features
  • Optimize management of potential adverse events with immunotherapeutic and targeted therapies used in the management of mCRC

CME Activity Table of Contents

  • Module 1: Introduction
  • Module 2: Medical Crossfire®: Individualizing Patient Care and Therapeutic Selection in mCRC
  • Module 3: Medical Crossfire®: Standards of Care in mCRC: Considerations Across Lines of Therapy
  • Module 4: Medical Crossfire®: Emerging Therapeutic Options in mCRC
  • Module 5: Medical Crossfire®: Best Practices for Management of Treatment-Related Toxicities in mCRC
  • Module 6: Conclusions

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen and Array BioPharma, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "Educational Content/Videos" will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, gastroenterologists, gastrointestinal oncologists, and surgical oncologists who treat patients with CRC. Other healthcare professionals who have an interest in the treatment of CRC, such as nurses, physician assistants, fellows, and residents, are also invited to participate.

Learning Objectives

After completion of this activity, you should be better prepared to:

  • Discuss the use of novel biomarkers and key testing technologies that can inform clinical decision making among patients with mCRC
  • Delineate the appropriate application of current guidelines and standards of care in patients with mCRC previously-treated with targeted, chemotherapeutic, and immunotherapeutic options
  • Examine new investigational clinical trial evidence, as well as key ongoing studies, of targeted treatments and their potential to impact management strategies in CRC treatment settings
  • Describe how common and uncommon adverse events can be proactively mitigated and managed for patients undergoing treatment for CRC

Faculty, Staff, and Planners' Disclosures


John L. Marshall
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Washington, DC

Disclosures: Grant/Research Support: Genentech, Amgen, Taiho, Bayer, Merck, Caris, Celgene, Ipsen; Consultant: Genentech, Amgen, Taiho, Bayer, Merck, Caris, Celgene, Ipsen; Speakers Bureau: Genentech, Amgen, Taiho, Bayer, Merck, Caris, Celgene, Ipsen


Ryan B. Corcoran
Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Scientific Director, Henri and Belinda Termeer Center for Targeted Therapies
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AstraZeneca, Sanofi, Asana; Consultant: Amgen, Astex Pharmaceuticals, Avidity Biosciences, BMS, FogPharma, Genentech, LOXO, Merrimack, N-of-One, Roche, Shire, Taiho, Symphogen, Warp Drive Bio, Array, Novartis, Chugai, nRichDX

Cathy Eng
Cathy Eng, MD, FACP
Director and Professor
Department of Gastrointestinal Medical Oncology
Associate Medical Director, Colorectal Center
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: LSK, Roche, Bayer

Marwan Fakih
Marwan Fakih, MD
Professor of Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Directorship in Clinical Research
Medical Director, Briskin Center for Clinical Research
Section Head, GI Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA

Disclosures: Grant/Research Support: Novartis, AstraZeneca; Consultant: Array, Seattle Genetics; Speakers Bureau: Amgen

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By